Associated Genetic Biomarkers
MUM1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain MUM1 status as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).
Trials with MUM1 status in the inclusion eligibility criteria most commonly target diffuse large B-cell lymphoma .
The most frequent alterations to serve as inclusion eligibility criteria are MUM1 Expression, MUM1 Overexpression, and PWWP domain-containing protein MUM1 Expression Positive .
Rituximab and toripalimab are the most frequent therapies in trials with MUM1 as an inclusion criteria .
Significance of MUM1 in Diseases
Diffuse Large B-Cell Lymphoma +
MUM1 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MUM1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) .
Primary Central Nervous System Lymphoma +
MUM1 is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MUM1 status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.